Palivizumab antibody | AbD23967_hIgG1

100% Secure


Human anti Palivizumab:HRP

Anti-palivizumab antibody is a recombinant, neutralizing, anti-idiotypic antibody in fully human IgG1 format for bioanalytical assays to measure palivizumab and biosimilars. It can be used as the detection antibody in a PK bridging ELISA and as a reference standard in an ADA bridging ELISA.

Human anti Palivizumab

Anti-palivizumab antibody is a recombinant, neutralizing, anti-idiotypic antibody in fully human IgG1 format for bioanalytical assays to measure palivizumab and biosimilars. It can be used as the detection antibody in a PK bridging ELISA and as a reference standard in an ADA bridging ELISA.

Product Type
Monoclonal Antibody
Clone
AbD23967_hIgG1
Isotype
IgG1
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
HCA262P E 0.1 mg
HCA262 E 0.1 mg
Human anti Palivizumab, clone AbD23967_hIgG1, is a paratope specific, high affinity, anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug palivizumab and inhibits it binding to its target. The antibody can be used to measure the levels of palivizumab and biosimilar products in bioanalytical assays.

Clone AbD23967_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a reference standard in an anti-drug antibody (ADA) assay. Additionally the antibody can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody is recommended as the detection antibody and is available unlabeled or directly conjugated to HRP. Use in a pair with capture antibody clone AbD23967 (HCA261) in monovalent Fab format.

Palivizumab (Synagis®) is a humanized mouse monoclonal antibody (IgG1/kappa) specific to an epitope of the F protein of respiratory syncytial virus (RSV). It binds the antigenic site A, a highly conserved region on the RSV F protein between amino acids 258 and 275. RSV is known to cause infections of the lower respiratory tract in a clear seasonal pattern during the winter months. Administration of the drug is recommended for premature infants (under 35 weeks gestation), infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD) throughout the duration of the RSV season. It is approved by the FDA and EMA as a treatment for respiratory tract infection caused by RSV.

View a summary of all anti-palivizumab antibodies

Product Details

Product Form
Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
Product Form
Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line.
Preparation
Purified IgG prepared by affinity chromatography on Protein A
Preparation
Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.01% Thiomersal
Preservative Stabilisers
0.01% Thiomersal
Immunogen
Palivizumab
Affinity
The monovalent intrinsic affinity of this antibody was measured as KD = 1.5 nM by real time, label free molecular interaction analysis on immobilized palivizumab.
Approx. Protein Concentrations
IgG concentration 0.1 mg/ml
Approx. Protein Concentrations
Antibody concentration 0.5 mg/ml

Storage Information

Storage
Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted.
Storage
Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life
12 months from date of despatch.
Shelf Life
12 months from date of despatch

More Information

Acknowledgements
Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Synagis® is a registered trademark of the AstraZeneca group of companies.
Acknowledgements
Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
Licensed Use
For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory
For research purposes only

Applications of Palivizumab antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
ELISA
ELISA
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
ELISA
This product may be used as a detection reagent in a sandwich ELISA together with HCA261 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug
ELISA
This product may be used in direct or indirect ELISA and in an ELISA bridging assay as a capture or detection antibody together with the same antibody or HCA261 as the paired reagent. It is also suitable as a fully human control or calibrator antibody in an ADA bridging ELISA.
Protocol: PK bridging ELISA to measure free drug

Useful Reagents Available

Description Product Code Pack Size Applications List Price Quantity
Hispec Assay Diluent BUF049A 50 ml E IY
Human anti Palivizumab HCA261 0.1 mg E
Human anti Palivizumab HCA262 0.1 mg E
Hispec Assay Diluent BUF049A 50 ml E IY
Human anti Palivizumab HCA261 0.1 mg E
LYNX Rapid HRP Antibody Conjugation Kit LNK002P 3 Conjugations For 400µg Antibody CJ

Product Specific References

References for Palivizumab antibody

  1. Kashiwagi, N. et al. (2017) Method for measuring anti-drug antibody
    US Patent Application US20170315118A1